Page last updated: 2024-12-05

benzenesulfonamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Benzenesulfonamide is a white, crystalline solid that is used as an intermediate in the synthesis of many pharmaceuticals, including sulfa drugs. It is also used as a reagent in organic synthesis. Benzenesulfonamide is a weak acid and is readily soluble in water. It is synthesized by the reaction of benzene with sulfuryl chloride, followed by treatment with ammonia. Benzenesulfonamide is a key intermediate in the synthesis of sulfonamides, a class of drugs that have a wide range of antibacterial activities. It is also used in the synthesis of other important compounds, such as dyes, herbicides, and pesticides. Benzenesulfonamide is studied because of its importance as a synthetic intermediate and its potential for use in the development of new pharmaceuticals.'

Cross-References

ID SourceID
PubMed CID7370
CHEMBL ID27601
CHEBI ID191017
SCHEMBL ID729
MeSH IDM0115105

Synonyms (58)

Synonym
EN300-15718
98-10-2
wln: zswr
nsc-5341
nsc5341
benzenesulfonamide
benzenesulphonamide
AB-131/40262287
einecs 202-637-1
ai3-04492
m and b 7973
brn 1100566
benzolsulfonamide
benzosulfonamide
nsc 5341
chembl27601 ,
bdbm12414
benzenesulfonamide, >=98%
STK325729
B0028
AKOS000144235
benzenesulonamide
CHEBI:191017
A845808
benzolsulfonamid
phenyl sulfonamide
phenylsulfonamide
benzenesulfonyl amine
benzene sulfonamide
S4725
ec 202-637-1
4-11-00-00050 (beilstein handbook reference)
FT-0622647
4JSA
4JSZ
AB01314414-03
SCHEMBL729
2WEJ
DTXSID1059159
benzensulfonamide
phenylsulphonamide
benzene sulphonamide
benzenesulfonic acid amide
benzene-sulfonamide
W-100094
CS-W020081
mfcd00007930
F1905-6988
benzenesulfonamide, vetec(tm) reagent grade, 98%
NCGC00340323-01
amosulalolhyorochloride
4C-038
Q818513
AMY37118
CCG-266270
SB75727
HY-101087
Z45415554
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (21)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 12Homo sapiens (human)IC50 (µMol)2.00000.00571.39908.5700AID50171
Carbonic anhydrase 1Homo sapiens (human)IC50 (µMol)2.00000.00582.14107.9000AID50171
Carbonic anhydrase 1Homo sapiens (human)Ki19.49920.00001.372610.0000AID1254399; AID1803133; AID644037
Carbonic anhydrase 2Homo sapiens (human)IC50 (µMol)2.00000.00021.10608.3000AID50171
Carbonic anhydrase 2Homo sapiens (human)Ki7.55490.00000.72369.9200AID1254400; AID1803133; AID644035; AID669115; AID729565
Carbonic anhydrase 2Bos taurus (cattle)Ki3.88180.00251.13257.5858AID550080
Carbonic anhydrase 3Homo sapiens (human)IC50 (µMol)2.00000.02001.66866.5000AID50171
Translocator proteinRattus norvegicus (Norway rat)Ki1.12000.00010.65108.9300AID644036
Carbonic anhydrase 4Homo sapiens (human)IC50 (µMol)2.00000.00320.31712.0000AID50171
Carbonic anhydrase 4Homo sapiens (human)Ki1.12000.00021.97209.9200AID644036
Carbonic anhydrase 6Homo sapiens (human)IC50 (µMol)2.00000.02001.33175.7900AID50171
Carbonic anhydrase 6Homo sapiens (human)Ki12.03650.00011.47109.9200AID1803133; AID644034
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)IC50 (µMol)2.00000.02003.10819.4000AID50171
Carbonic anhydrase 7Homo sapiens (human)IC50 (µMol)2.00000.02001.21363.4400AID50171
Platelet-activating factor acetylhydrolaseHomo sapiens (human)IC50 (µMol)1,000.00000.00000.38373.9000AID1308821
Carbonic anhydrase 9Homo sapiens (human)IC50 (µMol)2.00000.00030.63029.3900AID50171
Carbonic anhydrase Cryptococcus neoformans var. grubiiKi0.74600.01000.73648.3470AID669116
Carbonic anhydraseCandida albicans SC5314Ki2.36000.01051.44448.3470AID669117
Carbonic anhydrase 13Homo sapiens (human)IC50 (µMol)2.00000.02000.86802.0000AID50171
Carbonic anhydrase 14Homo sapiens (human)IC50 (µMol)2.00000.02000.53292.0000AID50171
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)IC50 (µMol)2.00000.02000.86802.0000AID50171
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Carbonic Anhydrase 2Homo sapiens (human)Kd0.83900.83900.98201.1250AID977611
Chain A, Carbonic Anhydrase 2Homo sapiens (human)Kd0.83900.83900.98201.1250AID977611
Chain A, Carbonic Anhydrase 2Homo sapiens (human)Kd0.83900.83900.98201.1250AID977611
Chain A, Carbonic Anhydrase 2Homo sapiens (human)Kd0.83900.83900.98201.1250AID977611
Carbonic anhydrase 12Homo sapiens (human)Kd12.50000.00070.29432.0000AID732710
Carbonic anhydrase 1Homo sapiens (human)Kd3.94330.00071.368910.0000AID1796897; AID732713
Carbonic anhydrase 2Homo sapiens (human)Kd458.29600.00000.41575.5500AID1307761; AID1307762; AID1796897; AID732712
Carbonic anhydrase 7Homo sapiens (human)Kd6.67000.00010.37616.6700AID732711
Platelet-activating factor acetylhydrolaseHomo sapiens (human)Kd3,400.00000.04970.04970.0497AID1308814
Carbonic anhydrase 13Homo sapiens (human)Kd10.00000.00070.384910.0000AID732709
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (29)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Bos taurus (cattle)
regulation of monoatomic anion transportCarbonic anhydrase 2Bos taurus (cattle)
regulation of intracellular pHCarbonic anhydrase 2Bos taurus (cattle)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Bos taurus (cattle)
response to bacteriumCarbonic anhydrase 3Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 3Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
peptide hormone processingPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
low-density lipoprotein particle remodelingPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
lipid oxidationPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
plasma lipoprotein particle oxidationPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
phosphatidylcholine catabolic processPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
platelet activating factor metabolic processPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
positive regulation of inflammatory responsePlatelet-activating factor acetylhydrolaseHomo sapiens (human)
platelet activating factor catabolic processPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
positive regulation of monocyte chemotaxisPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 13Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 14Homo sapiens (human)
response to bacteriumCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Bos taurus (cattle)
cyanamide hydratase activityCarbonic anhydrase 2Bos taurus (cattle)
carbonate dehydratase activityCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 3Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 3Homo sapiens (human)
nickel cation bindingCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
1-alkyl-2-acetylglycerophosphocholine esterase activityPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
phospholipid bindingPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
hydrolase activity, acting on ester bondsPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
calcium-independent phospholipase A2 activityPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 13Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 13Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 13Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Bos taurus (cattle)
plasma membraneCarbonic anhydrase 2Bos taurus (cattle)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytoplasmCarbonic anhydrase 3Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
extracellular regionPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
low-density lipoprotein particlePlatelet-activating factor acetylhydrolaseHomo sapiens (human)
high-density lipoprotein particlePlatelet-activating factor acetylhydrolaseHomo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
cytosolCarbonic anhydrase 13Homo sapiens (human)
myelin sheathCarbonic anhydrase 13Homo sapiens (human)
intracellular membrane-bounded organelleCarbonic anhydrase 13Homo sapiens (human)
cytoplasmCarbonic anhydrase 13Homo sapiens (human)
cytosolCarbonic anhydrase 13Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
membraneCarbonic anhydrase 14Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 14Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 14Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (56)

Assay IDTitleYearJournalArticle
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2013Inorganic chemistry, Nov-04, Volume: 52, Issue:21
Metalloprotein-inhibitor binding: human carbonic anhydrase II as a model for probing metal-ligand interactions in a metalloprotein active site.
AID237572Diuretic activity was determined2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Topological modeling of lipophilicity, diuretic activity, and carbonic inhibition activity of benzene sulfonamides: a molecular connectivity approach.
AID669116Inhibition of Cryptococcus neoformans Can2 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID50169Inhibitory activity against bovine Carbonic anhydrase1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
The binding of benzenesulfonamides to carbonic anhydrase enzyme. A molecular mechanics study and quantitative structure-activity relationships.
AID239935Inhibition constant against carbonic anhydrase2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Novel use of chemical shift in NMR as molecular descriptor: a first report on modeling carbonic anhydrase inhibitory activity and related parameters.
AID1308814Binding affinity to N-terminal His6-tagged Lp-PLA2 (47 to 429 residues) (unknown origin) expressed in sf21 insect cells by ITC assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.
AID237422Partition coefficient (logP)2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Topological modeling of lipophilicity, diuretic activity, and carbonic inhibition activity of benzene sulfonamides: a molecular connectivity approach.
AID732713Binding affinity to human recombinant CA1 at 37 degC and pH 7.0 by thermal shift assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
4-Substituted-2,3,5,6-tetrafluorobenzenesulfonamides as inhibitors of carbonic anhydrases I, II, VII, XII, and XIII.
AID1307759Binding affinity to GST-fused human carbonic anhydrase-2 expressed in Escherichia coli BL21 codon plus cells assessed as association kinetic constant by SPR method2016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
Kinetic and Structural Insights into the Mechanism of Binding of Sulfonamides to Human Carbonic Anhydrase by Computational and Experimental Studies.
AID1254400Inhibition of cytosolic carbonic anhydrase 2 esterase activity isolated from human serum using 4-nitrophenylacetate as substrate measured over 3 mins by spectrophotometric analysis2015Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23
Carbonic anhydrase inhibitors: Design, synthesis, kinetic, docking and molecular dynamics analysis of novel glycine and phenylalanine sulfonamide derivatives.
AID1307762Binding affinity to GST-fused human carbonic anhydrase-2 expressed in Escherichia coli BL21 codon plus cells assessed as steady state dissociation constant by SPR method2016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
Kinetic and Structural Insights into the Mechanism of Binding of Sulfonamides to Human Carbonic Anhydrase by Computational and Experimental Studies.
AID644036Inhibition of human carbonic anhydrase 4 esterase activity using 4-nitrophenylacetate as substrate2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and carbonic anhydrase inhibitory properties of novel cyclohexanonyl bromophenol derivatives.
AID1123579Inhibition of carbonic anhydrase (unknown origin) relative to sulfanilamide1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Correlation of carbonic anhydrase inhibitory activities of benzenesulfonamides with the data obtained by use of nitrogen-14 nuclear quadrupole resonance.
AID1134600Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID729567Inhibition of sheep kidney esterase activity of carbonic anhydrase using 4-nitrophenylacetate as substrate after 3 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
Purification and characterization of carbonic anhydrase from sheep kidney and effects of sulfonamides on enzyme activity.
AID669120Antimicrobial activity against Malassezia furfur CBS 9569 after 7 days2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID1308821Inhibition of human recombinant Lp-PLA2 using PED6 as substrate preincubated for 30 mins followed by substrate addition measured for 20 mins by fluorescence assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.
AID50171In vitro inhibition of crude dog red blood cell carbonic anhydrase1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Sulfonylmethanesulfonamide inhibitors of carbonic anhydrase.
AID669115Inhibition of human carbonic anhydrase 2 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID669117Inhibition of Candida albicans CaNce103 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID669119Inhibition of GST-tagged Malassezia globosa ATCC 96807/CBS 7966 MG-CA expressed in Escherichia coli BL21(DE3) cells preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID1205837Binding affinity to cobalt (II)-substituted bovine alpha-carbonic anhydrase assessed as compound-enzyme adduct formation at 12 uM after 10 to 15 mins by UV-visible spectroscopy2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
α-Carbonic Anhydrases Possess Thioesterase Activity.
AID550080Binding affinity to bovine carbonic anhydrase 22011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Correlation analyses on binding affinity of substituted benzenesulfonamides with carbonic anhydrase using ab initio MO calculations on their complex structures (II).
AID244692Diuretic activity was determined2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Novel use of chemical shift in NMR as molecular descriptor: a first report on modeling carbonic anhydrase inhibitory activity and related parameters.
AID669122Antimicrobial activity against Malassezia pachydermatis CBS 6536 after 7 days2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID732711Binding affinity to human recombinant CA7 at 37 degC and pH 7.0 by thermal shift assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
4-Substituted-2,3,5,6-tetrafluorobenzenesulfonamides as inhibitors of carbonic anhydrases I, II, VII, XII, and XIII.
AID729565Inhibition of human esterase activity of carbonic anhydrase 2 using 4-nitrophenylacetate as substrate after 3 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
Purification and characterization of carbonic anhydrase from sheep kidney and effects of sulfonamides on enzyme activity.
AID1254399Inhibition of cytosolic carbonic anhydrase 1 esterase activity isolated from human serum using 4-nitrophenylacetate as substrate measured over 3 mins by spectrophotometric analysis2015Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23
Carbonic anhydrase inhibitors: Design, synthesis, kinetic, docking and molecular dynamics analysis of novel glycine and phenylalanine sulfonamide derivatives.
AID1134599CHCl3-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID644035Inhibition of human carbonic anhydrase 2 esterase activity using 4-nitrophenylacetate as substrate2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and carbonic anhydrase inhibitory properties of novel cyclohexanonyl bromophenol derivatives.
AID669121Antimicrobial activity against Malassezia dermatis CBS 9145 after 7 days2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID1307761Binding affinity to GST-fused human carbonic anhydrase-2 expressed in Escherichia coli BL21 codon plus cells assessed as dissociation constant by SPR method2016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
Kinetic and Structural Insights into the Mechanism of Binding of Sulfonamides to Human Carbonic Anhydrase by Computational and Experimental Studies.
AID1893771Inhibition of recombinant human QC using H-Gln-AMC hydrobromide as fluorogenic substrate incubated for 6 hrs by fluorometric microplate reader analysis2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint.
AID28956Partition coefficient (logP) (dodecane)2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Rational determination of transfer free energies of small drugs across the water-oil interface.
AID644037Inhibition of human carbonic anhydrase 1 esterase activity using 4-nitrophenylacetate as substrate2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and carbonic anhydrase inhibitory properties of novel cyclohexanonyl bromophenol derivatives.
AID669123Antimicrobial activity against Malassezia globosa CBS 7966 after 7 days2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID1852388Inhibition of Carbonic anhydrase (unknown origin)2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Hypoxia-Activated Prodrugs with Dual COX-2/CA Inhibitory Effects on Attenuating Cardiac Inflammation under Hypoxia.
AID50340Binding constant of ligand was determined by Affinity capillary electrophoresis (ACE) using bovine carbonic anhydrase-B1993Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1
Use of affinity capillary electrophoresis to determine kinetic and equilibrium constants for binding of arylsulfonamides to bovine carbonic anhydrase.
AID28957Partition coefficient (logP)2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Rational determination of transfer free energies of small drugs across the water-oil interface.
AID732710Binding affinity to human recombinant CA12 at 37 degC and pH 7.0 by thermal shift assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
4-Substituted-2,3,5,6-tetrafluorobenzenesulfonamides as inhibitors of carbonic anhydrases I, II, VII, XII, and XIII.
AID732712Binding affinity to human recombinant CA2 at 37 degC and pH 7.0 by thermal shift assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
4-Substituted-2,3,5,6-tetrafluorobenzenesulfonamides as inhibitors of carbonic anhydrases I, II, VII, XII, and XIII.
AID1123580Inhibition of carbonic anhydrase (unknown origin) at 0.2 degC1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Correlation of carbonic anhydrase inhibitory activities of benzenesulfonamides with the data obtained by use of nitrogen-14 nuclear quadrupole resonance.
AID50176Binding affinity against human carbonic anhydrase (hCA).1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Simple linear QSAR models based on quantum similarity measures.
AID644034Inhibition of human carbonic anhydrase 6 esterase activity using 4-nitrophenylacetate as substrate2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and carbonic anhydrase inhibitory properties of novel cyclohexanonyl bromophenol derivatives.
AID239922Inhibitory activity against carbonic anhydrase2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Topological modeling of lipophilicity, diuretic activity, and carbonic inhibition activity of benzene sulfonamides: a molecular connectivity approach.
AID1123578Inhibition of carbonic anhydrase (unknown origin) at 15 degC1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Correlation of carbonic anhydrase inhibitory activities of benzenesulfonamides with the data obtained by use of nitrogen-14 nuclear quadrupole resonance.
AID1307760Binding affinity to GST-fused human carbonic anhydrase-2 expressed in Escherichia coli BL21 codon plus cells assessed as dissociation kinetic constant by SPR method2016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
Kinetic and Structural Insights into the Mechanism of Binding of Sulfonamides to Human Carbonic Anhydrase by Computational and Experimental Studies.
AID1136505Inhibition of carbonic anhydrase (unknown origin)1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
A manual method for applying the Hansch approach to drug design.
AID23443Partition coefficient (logP)1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Use of physicochemical parameters in distance geometry and related three-dimensional quantitative structure-activity relationships: a demonstration using Escherichia coli dihydrofolate reductase inhibitors.
AID243139Binding constant against human Carbonic anhydrase II2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
QSAR studies on benzene sulfonamide carbonic anhydrase inhibitors: need of hydrophobic parameter for topological modeling of binding constants of sulfonamides to human CA-II.
AID237031Partition coefficient (logP)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Novel use of chemical shift in NMR as molecular descriptor: a first report on modeling carbonic anhydrase inhibitory activity and related parameters.
AID732709Binding affinity to human recombinant CA13 at 37 degC and pH 7.0 by thermal shift assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
4-Substituted-2,3,5,6-tetrafluorobenzenesulfonamides as inhibitors of carbonic anhydrases I, II, VII, XII, and XIII.
AID243144Partition coefficient (logP)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
QSAR studies on benzene sulfonamide carbonic anhydrase inhibitors: need of hydrophobic parameter for topological modeling of binding constants of sulfonamides to human CA-II.
AID1796897Competitive Displacement Binding Assay from Article 10.1021/ja057257n: \\Ultrahigh resolution crystal structures of human carbonic anhydrases I and II complexed with "two-prong" inhibitors reveal the molecular basis of high affinity.\\2006Journal of the American Chemical Society, Mar-08, Volume: 128, Issue:9
Ultrahigh resolution crystal structures of human carbonic anhydrases I and II complexed with "two-prong" inhibitors reveal the molecular basis of high affinity.
AID1803133CA Activity Assay from Article 10.3109/14756366.2011.614607: \\Chromone containing sulfonamides as potent carbonic anhydrase inhibitors.\\2012Journal of enzyme inhibition and medicinal chemistry, Oct, Volume: 27, Issue:5
Chromone containing sulfonamides as potent carbonic anhydrase inhibitors.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2009ChemMedChem, Dec, Volume: 4, Issue:12
Thermodynamic optimisation in drug discovery: a case study using carbonic anhydrase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (18.52)18.7374
1990's3 (11.11)18.2507
2000's6 (22.22)29.6817
2010's11 (40.74)24.3611
2020's2 (7.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.27 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index61.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 2a Study Evaluating a Chemokine-Modulatory Regimen in Patients With Colorectal Cancer Metastatic to the Liver [NCT03403634]Phase 219 participants (Actual)Interventional2018-04-19Completed
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME [NCT03878524]Phase 12 participants (Actual)Interventional2020-04-01Active, not recruiting
Randomized Study of Pre-Prostatectomy Celecoxib or Placebo [NCT02840162]Phase 234 participants (Actual)Interventional2001-05-31Terminated(stopped due to Drug safety concerns)
Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer [NCT05756166]Phase 1/Phase 212 participants (Anticipated)Interventional2023-12-30Not yet recruiting
RESILIENCE: Effect of Comprehensive Celecoxib Through Treatment for Advanced-Stage Head and Neck Cancer: A Randomized, Double-Blinded, Placebo-Controlled Trial [NCT04162873]Phase 260 participants (Anticipated)Interventional2019-11-27Recruiting
Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer [NCT04081389]Phase 19 participants (Actual)Interventional2019-12-06Completed
A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3) [NCT00081263]Phase 2130 participants (Actual)Interventional2005-06-30Completed
A Phase II Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer [NCT01729923]Phase 227 participants (Actual)Interventional2013-03-31Terminated(stopped due to Funding ended)
Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer [NCT03599453]Early Phase 18 participants (Actual)Interventional2019-01-09Completed
A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance [NCT04093323]Phase 224 participants (Anticipated)Interventional2023-12-31Suspended(stopped due to IFNa2b supply shortage)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00081263 (2) [back to overview]Histologic Regression
NCT00081263 (2) [back to overview]Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events Version 3.0
NCT01729923 (5) [back to overview]Best Overall Response Rate Among All Patients Who Had RECIST Measurements at Baseline and at Least One Subsequent Occasion
NCT01729923 (5) [back to overview]Best Overall Response Rate Among All Patients Who Had RECIST Measurements at Baseline and at Least One Subsequent Occasion and Did Not Have Surgery or Radiation Therapy
NCT01729923 (5) [back to overview]Overall Survival
NCT01729923 (5) [back to overview]Rate of CR, Assessed According to CEA and CA 19-9 Measurements and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
NCT01729923 (5) [back to overview]Relapse Free Survival in Patients Achieving CR
NCT03403634 (4) [back to overview]Change in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions
NCT03403634 (4) [back to overview]Objective Response Rate (ORR) Assessed by Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1
NCT03403634 (4) [back to overview]Overall Survival
NCT03403634 (4) [back to overview]Progression Free Survival
NCT04081389 (4) [back to overview]Number of Patients With Dose Limiting Toxicities
NCT04081389 (4) [back to overview]Number of Patients With Pathological Complete Response (pCR)
NCT04081389 (4) [back to overview]Overall Survival (OS)
NCT04081389 (4) [back to overview]Recurrence-free Survival (RFS)

Histologic Regression

Whether or not patients with CIN 2/3 or CIN 3 upon entry experience a complete remission (or partial regression to CIN 1) in the post-treatment excisional biopsy. (NCT00081263)
Timeframe: Post treatment evaluation was done 14 to 18 weeks after treatment randomization

Interventionpercentage of participants (Number)
Arm I (Celecoxib)40
Arm II (Placebo)34.1

[back to top]

Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events Version 3.0

Number of participants with a grade of 3 or higher during the treatment period. (NCT00081263)
Timeframe: Assessed every cycle while on treatment, 30 days after the last cycle of treatment

,
Interventionparticipants (Number)
GastrointestinalPain
Arm I (Celecoxib)10
Arm II (Placebo)01

[back to top]

Best Overall Response Rate Among All Patients Who Had RECIST Measurements at Baseline and at Least One Subsequent Occasion

RECIST 1.1 criteria will be used to measure changes in the size of a selected sentinel lesion for each patient. Computed tomographic images will be measured at baseline and at subsequent 9 week intervals. Changes will be measured as percentage of the baseline measure. Results will be reported as the largest negative change. For patients with no negative changes, results will be reported as the smallest positive change. (NCT01729923)
Timeframe: Serial measures at 9 week intervals up to 5 years

Interventionpercentage of baseline lesion size (Mean)
Capecitabine and Celecoxib-17

[back to top]

Best Overall Response Rate Among All Patients Who Had RECIST Measurements at Baseline and at Least One Subsequent Occasion and Did Not Have Surgery or Radiation Therapy

RECIST 1.1 criteria will be used to measure changes in the size of a selected sentinel lesion for each patient. Computed tomographic images will be measured at baseline and at subsequent 9 week intervals. Changes will be measured as percentage of the baseline measure. Results will be reported as the largest negative change. For patients with no negative changes, results will be reported as the smallest positive change. (NCT01729923)
Timeframe: Serial measures at 9 week intervals up to 5 years

Interventionpercentage of baseline lesion size (Mean)
Capecitabine and Celecoxib11

[back to top]

Overall Survival

Estimated using the Kaplan-Meier method based on the ITT population starting from the time of induction chemotherapy initiation until death or last reported survival. (NCT01729923)
Timeframe: Until death or last reported survival, up to 5 years

Interventionmonths (Median)
Capecitabine and Celecoxib15

[back to top]

Rate of CR, Assessed According to CEA and CA 19-9 Measurements and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor marker level in response to ADAPT therapy. (NCT01729923)
Timeframe: 3 years

InterventionParticipants (Count of Participants)
Capecitabine and Celecoxib1

[back to top]

Relapse Free Survival in Patients Achieving CR

Relapse-free survival estimated using the Kaplan-Meier method based on the ITT population starting from the time of induction chemotherapy initiation. (NCT01729923)
Timeframe: Up to 5 years

Interventionmonths (Number)
Capecitabine and Celecoxib7

[back to top]

Change in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions

"The TILs will be summarized by time-point (pre-/post-treatment) using the mean, median, standard deviation; and graphically using dot-plots.~The TIL of interest is CD8a expression, which is reported as the mean fold change from pre-treatment (i.e. post treatment / pre treatment)." (NCT03403634)
Timeframe: Baseline up to 12 months

Interventionfold change (Mean)
Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)7.25

[back to top]

Objective Response Rate (ORR) Assessed by Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1

Will be treated as binary data and summarized using frequencies and relative frequencies; with the ORR estimated using a 90% confidence interval obtained using Jeffrey's prior method. (NCT03403634)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)0

[back to top]

Overall Survival

Will be treated as bivariate time-to-event data and will be summarized using standard Kaplan-Meier methods. (NCT03403634)
Timeframe: From the start of treatment until death due to any cause or last follow-up, assessed up to 12 months

InterventionMonths (Median)
Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)10.5

[back to top]

Progression Free Survival

Will be treated as bivariate time-to-event data and will be summarized using standard Kaplan-Meier methods. (NCT03403634)
Timeframe: From the start of treatment until disease progression (defined by RECIST 1.1) or last-follow-up, assessed up to 12 months

InterventionMonths (Median)
Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)1.5

[back to top]

Number of Patients With Dose Limiting Toxicities

"Safety and toxicity will be assessed using the CTEP NCI Common Terminology Criteria for Adverse Events (CTCAE Version 5.0). The resulting dose limiting toxicity (DLT) information is used to identify the appropriate dose level of CKM and paclitaxel for future clinical exploration.~The following events will be considered a DLT:~The event occurs within 3 weeks following 1st dose of combination CKM + paclitaxel therapy and subsequent enrollment for dose-escalation will only proceed after the 3-week period has been completed.~The toxicity has been determined by the investigator to be possibly, probably or definitely related to celecoxib, rintatolimod, interferon-α2b or paclitaxel.~Any death not clearly due to th" (NCT04081389)
Timeframe: Within 21 days of treatment adminstration

InterventionParticipants (Count of Participants)
Arm 1: Interferon Alpha-2b at DL 10
Arm 2: Interferon Alpha-2b at DL 20
Arm 3: Interferon Alpha-2b at DL 30
Arm 4: Interferon Alpha-2b at DL 40

[back to top]

Number of Patients With Pathological Complete Response (pCR)

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI, where Complete Response (CR) corresponds to the disappearance of all target lesions. (NCT04081389)
Timeframe: Up to 4 week post-treatment (with a range of 7 to 11 weeks).

InterventionParticipants (Count of Participants)
Arm 1: Interferon Alpha-2b at DL 10
Arm 2: Interferon Alpha-2b at DL 21
Arm 3: Interferon Alpha-2b at DL 32
Arm 4: Interferon Alpha-2b at DL 42

[back to top]

Overall Survival (OS)

OS is defined by death from breast cancer, non-breast cancer, unknown, or any other cause and will be calculated from the time of study entry to event. The median OS is estimated using standard Kaplan-Meier methods (where NR = not reached). (NCT04081389)
Timeframe: At 3 years

Interventionmonths (Median)
Arm 1: Interferon Alpha-2b at DL 121.7
Arm 2: Interferon Alpha-2b at DL 2NA
Arm 3: Interferon Alpha-2b at DL 3NA
Arm 4: Interferon Alpha-2b at DL 4NA

[back to top]

Recurrence-free Survival (RFS)

RFS is defined as local/regional invasive recurrence, invasive ipsilateral breast tumor recurrence, distant recurrence, inoperable (meaning no surgery because of progression), and/or death from breast cancer (per standard of care according to physician discretion) or any cause. RFS will be calculated from the time of treatment to event. The median RFS was estimated using standard Kaplan-Meier methods (where NR = not reached). (NCT04081389)
Timeframe: At 3 years

Interventionmonths (Median)
Arm 1: Interferon Alpha-2b at DL 112.0
Arm 2: Interferon Alpha-2b at DL 2NA
Arm 3: Interferon Alpha-2b at DL 311.4
Arm 4: Interferon Alpha-2b at DL 411.5

[back to top]